Seaport Therapeutics, Inc Common Stock
Yahoo Finance • 2 days ago
PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
This article first appeared on GuruFocus. Release Date: September 22, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points PureTech Health PLC ended H1 2026 with $220... Full story
Yahoo Finance • 3 days ago
PureTech Health H1 Earnings Call Highlights
Key Points Interested in PureTech Health PLC Sponsored ADR? Here are five stocks we like better. PureTech reported $220 million in cash and short-term investments at the parent-company level and expects its operational runway to last thro... Full story
Yahoo Finance • 30 days ago
Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls
Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compile... Full story
Yahoo Finance • last month
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
Quick Read SPTX's Glyph prodrug platform has generated 24 candidates, with lead asset GlyphAllo entering Phase 2b for MDD and topline results expected in 1H 2027. BMY previously paid $14 billion for Karuna Therapeutics, co-founded by Seap... Full story
Yahoo Finance • 4 months ago
Seaport Therapeutics Reports Wider Net Loss In Q1; Expects Phase 2b BUOY-1 Trial Data In H1,2027
(RTTNews) - Seaport Therapeutics, Inc. (SPTX), reported a wider net loss for its first financial quarter ended March 31, 2026, and provided near term milestone update. Company Profile Seaport Therapeutics is a clinical-stage therapeutics... Full story
Yahoo Finance • 4 months ago
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
New data from Phase 1 trial of GlyphAgoTM build upon previously reported topline data and further demonstrate GlyphAgoTM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eli... Full story
- JNJ